Cover Image

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	British Journal of Clinical Pharmacology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bruton's tyrosine kinase inhibition suppresses pathological retinal angiogenesis
by: Siyue Chen, et al.
Published: (2024)

Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects
by: Zhili Jin, et al.
Published: (2026)

Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
by: Yue Wu, et al.
Published: (2024)

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases
by: Henning Olbrich, et al.
Published: (2026)

Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database
by: Zeng‐Xiang Zhao, et al.
Published: (2024)

Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers
by: Lisanne K. A. Neijenhuis, et al.
Published: (2026)

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
by: Yuhao Wang, et al.
Published: (2025)

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
by: Irina Baltcheva, et al.
Published: (2026)

Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
by: C. Hu, et al.
Published: (2025)

Hand–foot skin reaction as a positive prognostic factor in vascular endothelial growth factor receptor‐tyrosine kinase inhibitor treatment
by: I‐Hsin Huang, et al.
Published: (2026)

Formulation breakthroughs driving broader tyrosine kinase use
by: Hans Lennernäs, et al.
Published: (2026)

Evaluation of the acute effects of single‐dose TPN171 on semen quality in healthy Chinese male volunteers
by: Yuzhuo Yang, et al.
Published: (2025)

Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection
Published: (2024)

Targeting the tyrosine kinase Src in endothelium attenuates inflammation and atherogenesis induced by disturbed flow
by: Huanyu Ding, et al.
Published: (2024)

The first in‐human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT‐678 in acute coronary syndrome patients and healthy volunteers
by: Zhihao Liu, et al.
Published: (2024)

Establishing reference ranges for circulating biomarkers of drug‐induced liver injury in healthy human volunteers 1
by: Andrea L. Jorgensen, et al.
Published: (2024)

Why do healthy volunteers participate in clinical trials?
by: Thijs van Iersel, et al.
Published: (2026)

Inhibition of proline‐rich tyrosine kinase 2 restores cardioprotection by remote ischaemic preconditioning in type 2 diabetes
by: Ralf Erkens, et al.
Published: (2024)

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
by: Jean‐Yves Gillon, et al.
Published: (2025)

Effects on cerebral blood flow after single doses of the β2 agonist, clenbuterol, in healthy volunteers and patients with mild cognitive impairment or Parkinson's disease
by: Thomas Lodeweyckx, et al.
Published: (2024)

A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers
by: Yanina Hiriart, et al.
Published: (2024)

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants
by: Mohammad Ghasemi, et al.
Published: (2025)

Therapeutic targeting of GSK‐3β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ‐2412, a novel sunitinib analogue
by: Kiran Yadav, et al.
Published: (2026)

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies
by: Alexandra A. J. Sillé, et al.
Published: (2026)

Pharmacological targeting of large tumor suppressor kinases (LATS) 1 and 2 augments tissue repair and regeneration
by: Chen Xiao, et al.
Published: (2025)

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults
by: Sven C. van Dijkman, et al.
Published: (2026)

Janus kinase inhibitors for the treatment of lichen Sclerosus: A systematic review
by: Chin‐Hsuan Shen, et al.
Published: (2025)

Pharmacological inhibition of the interleukin‐1 receptor‐associated kinase prevents angiotensin II‐induced cardiac remodelling in mice
by: Shreya Jaiswal, et al.
Published: (2026)

Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men
by: Christian Friedrich, et al.
Published: (2024)

Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease
by: Muhammad Waqas Sadiq, et al.
Published: (2024)

Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial
by: Alexander Hincker, et al.
Published: (2024)

Pharmacokinetic parameters of bictegravir in breastmilk of healthy, lactating volunteers without HIV after a single dose of 50 mg (co‐formulated with emtricitabine 200 mg and tenofovir alafenamide 25 mg)
by: L. Van Der Wekken‐Pas, et al.
Published: (2025)

Role of protein kinase A and A kinase anchoring proteins in buffering and compartmentation of cAMP signalling in human airway smooth muscle cells
by: Rinzhin T. Sherpa, et al.
Published: (2024)

Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)—Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499
by: Kasra Shakeri‐Nejad, et al.
Published: (2026)

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy
by: Zihan Qu, et al.
Published: (2024)

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma
by: Anna Lundahl, et al.
Published: (2025)

Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
by: Kexu Yang, et al.
Published: (2026)

Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
by: C. Hu, et al.
Published: (2025)

A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects
by: Yusuke Tadayasu, et al.
Published: (2024)

Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individuals
by: Chen Xia, et al.
Published: (2026)